KR100992981B1 - 의료 및 진단 절차에 사용하기 위한 조영제 및 그 이용 방법 - Google Patents
의료 및 진단 절차에 사용하기 위한 조영제 및 그 이용 방법 Download PDFInfo
- Publication number
- KR100992981B1 KR100992981B1 KR1020087029742A KR20087029742A KR100992981B1 KR 100992981 B1 KR100992981 B1 KR 100992981B1 KR 1020087029742 A KR1020087029742 A KR 1020087029742A KR 20087029742 A KR20087029742 A KR 20087029742A KR 100992981 B1 KR100992981 B1 KR 100992981B1
- Authority
- KR
- South Korea
- Prior art keywords
- contrast
- contrast medium
- present
- sorbitol
- imaging
- Prior art date
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 150
- 229940039231 contrast media Drugs 0.000 title claims description 7
- 238000002405 diagnostic procedure Methods 0.000 title abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 81
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims abstract description 64
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 36
- 238000003384 imaging method Methods 0.000 claims abstract description 33
- 239000003381 stabilizer Substances 0.000 claims abstract description 23
- 239000002357 osmotic agent Substances 0.000 claims abstract description 19
- 210000003484 anatomy Anatomy 0.000 claims abstract description 17
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 27
- 239000000600 sorbitol Substances 0.000 claims description 27
- 235000010356 sorbitol Nutrition 0.000 claims description 27
- 210000000813 small intestine Anatomy 0.000 claims description 16
- 229920001285 xanthan gum Polymers 0.000 claims description 14
- 235000010493 xanthan gum Nutrition 0.000 claims description 13
- 239000000230 xanthan gum Substances 0.000 claims description 13
- 229940082509 xanthan gum Drugs 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 210000002784 stomach Anatomy 0.000 claims description 9
- 210000001165 lymph node Anatomy 0.000 claims description 7
- 210000000496 pancreas Anatomy 0.000 claims description 7
- 210000000952 spleen Anatomy 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 5
- 210000002429 large intestine Anatomy 0.000 claims description 5
- 210000000232 gallbladder Anatomy 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- 231100000397 ulcer Toxicity 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 210000004534 cecum Anatomy 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000001198 duodenum Anatomy 0.000 claims description 3
- 210000003405 ileum Anatomy 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 210000001630 jejunum Anatomy 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 2
- 210000001599 sigmoid colon Anatomy 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 80
- 238000009472 formulation Methods 0.000 abstract description 74
- 150000001875 compounds Chemical class 0.000 abstract description 22
- 229910052788 barium Inorganic materials 0.000 abstract description 10
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 abstract description 10
- -1 hounsfield value Substances 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 238000002591 computed tomography Methods 0.000 description 52
- 230000000968 intestinal effect Effects 0.000 description 36
- 238000002595 magnetic resonance imaging Methods 0.000 description 27
- 210000001015 abdomen Anatomy 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000000936 intestine Anatomy 0.000 description 13
- 238000002600 positron emission tomography Methods 0.000 description 12
- 210000005166 vasculature Anatomy 0.000 description 12
- 230000004888 barrier function Effects 0.000 description 11
- 238000002059 diagnostic imaging Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 10
- 210000004872 soft tissue Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 238000002604 ultrasonography Methods 0.000 description 9
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 239000011630 iodine Substances 0.000 description 8
- 238000012831 peritoneal equilibrium test Methods 0.000 description 8
- 238000012636 positron electron tomography Methods 0.000 description 8
- 238000012877 positron emission topography Methods 0.000 description 8
- 239000008213 purified water Substances 0.000 description 7
- 230000003187 abdominal effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000021251 pulses Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000000440 bentonite Substances 0.000 description 5
- 229910000278 bentonite Inorganic materials 0.000 description 5
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229920001903 high density polyethylene Polymers 0.000 description 5
- 239000004700 high-density polyethylene Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229910052688 Gadolinium Inorganic materials 0.000 description 4
- 229920000161 Locust bean gum Polymers 0.000 description 4
- 240000008790 Musa x paradisiaca Species 0.000 description 4
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000010420 locust bean gum Nutrition 0.000 description 4
- 239000000711 locust bean gum Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000004197 pelvis Anatomy 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000013570 smoothie Nutrition 0.000 description 4
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001553 barium compounds Chemical class 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000013170 computed tomography imaging Methods 0.000 description 3
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001839 endoscopy Methods 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940083037 simethicone Drugs 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000003384 transverse colon Anatomy 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000032115 Mendelian susceptibility to mycobacterial disease Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 210000001731 descending colon Anatomy 0.000 description 2
- 238000007435 diagnostic evaluation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000013751 inherited susceptibility to mycobacterial disease Diseases 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002357 laparoscopic surgery Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N D-Galacturonic acid Natural products O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010022642 Intestinal dilatation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 229910052914 metal silicate Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 229940061368 sonata Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0404—X-ray contrast preparations containing barium sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- High Energy & Nuclear Physics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
Description
조직 | 표준값 (HV) |
범위 (HV) |
유체 | 표준값 (HV) |
골(고밀도) 골(스펀지) 갑상선 간 근육 지라 림프종 췌장 신장 지방조직 |
>250 130±100 70±10 65±5 45±5 45±5 45±5 40±10 30±10 -90±10 |
45∼75 35∼50 35∼55 40∼60 25∼55 20∼40 -80∼(-110) |
혈액(응고된) 혈액(정맥성 혈액) 혈장 삼출물 (>30g단백질/l) 누출액 (>30g단백질/l) 링거액 |
80±10 55±5 27±2 >18±2 <18±2 12±2 |
성분 |
A 포뮬레이션 % w/v |
B 포뮬레이션 % w/v |
C 포뮬레이션 % w/v |
D 포뮬레이션 % w/v |
성분의 기능 |
황산바륨 USP, EP |
0.0000 | 0.1000 | 0.0500 | 0.0500 | 방사선 사진 조영제 |
크산탄 검 NF |
0.5226 | 0.1828 | 0.5226 | 0.1830 | 현탁 안정화제 |
소르비톨 용액 70%, USP |
3.7616 | 2.8571 | 2.0000 | 2.0000 | 삼투압 조절제 |
점도 | 719cps | 128cps | 860cps | 140cps | |
밀도 | 1.0100g/ml | 1.0100g/ml | 1.006g/ml | 1.005ag/ml | |
pH | 4.95 | 4.95 | 5 | 5 | |
포타슘 소르베 이트, NF |
0.2090 |
방부제 |
|||
벤조산나트륨 NF |
0.0433 |
||||
벤조산 USP/BP |
0.0696 |
||||
시메티콘 에멀전, USP |
0.5226 |
소포제 |
|||
시트르산 USP |
0.0028 |
pH 조절제 |
|||
시트르산 나트륨,USP |
0.0076 |
||||
향료 및 인공감미료 |
0.4309 |
향료 |
|||
정제수 USP |
q.s 내지 100 체적% |
희석제 |
설명 | 양 (%) | |
1 | 정제수, USP | 66.6700 체적% |
2 | 크산탄 검, NF/EP/BP | 0.0914 w/v% |
3 | 시메티콘 에멀전 30%, USP | 0.0673 w/v% |
4 | 정제수, USP | 0.0716 체적% |
5 | 포타슘소르베이트, NF | 0.2090 w/v% |
6 | 벤조산나트륨,NF | 0.0433 w/v% |
7 | 벤조산, USP/BP | 0.0696 w/v% |
8 | 시트르산나트륨 이수화물, USP/EURPH | 0.0076 w/v% |
9 | 시트르산 무수물, USP | 0.0028 w/v% |
10 | 정제수, USP | 0.5556 체적% |
11 | 황산바륨, HN USP | 0.1000 w/v% |
12 | 크산탄 검, NF/EP/BP | 0.0914 w/v% |
13 | 시메티콘 에멀전, USP | 0.4553 w/v% |
14 | 정제수, USP | 0.4840 체적% |
15 | 소르비톨 용액 70%, USP | 2.8571 w/v% |
16 | 소듐 사카린, USP/EP/BP | 0.0109 w/v% |
17 | SAV BLEUET W390007F MFR | 0.1500 w/v% |
18 | 정제수, USP | QS |
Claims (22)
- 0.01 내지 0.2 w/v%의 황산바륨을 포함하는 조영제(constrast agent) 및 0.005 내지 70 w/v%의 소르비톨, 만니톨 및 크실리톨로 이루어진 군으로부터 선택되는 당계 삼투제를 포함하며, 0 내지 50의 하운스필드 값(Hounsfield value)을 가지고, 수계 현탁액 중에 제공되는 것을 특징으로 하는, 개체의 해부학적 부분(anatomic segment)을 영상화하는 데 사용되는 조영 매질(contrast media).
- 제1항에 있어서,상기 하운스필드 값이 5 내지 50인 것을 특징으로 하는 조영 매질.
- 제1항에 있어서,상기 하운스필드 값이 5 내지 45인 것을 특징으로 하는 조영 매질.
- 제1항에 있어서,상기 하운스필드 값이 15 내지 35인 것을 특징으로 하는 조영 매질.
- 제1항에 있어서,상기 하운스필드 값이 20 내지 30인 것을 특징으로 하는 조영 매질.
- 제1항에 있어서,상기 황산바륨의 농도가 0.02 w/v%, 0.03 w/v%, 0.04 w/v%, 0.06 w/v%, 0.07 w/v%, 0.08 w/v%, 0.09 w/v%, 0.11 w/v%, 및 0.15 w/v%로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 조영 매질.
- 제1항에 있어서,안정화제를 추가로 포함하는 것을 특징으로 하는 조영 매질.
- 제1항에 있어서,0.005 w/v% 내지 40 w/v%의 안정화제를 추가로 포함하는 것을 특징으로 하는 조영 매질.
- 제1항에 있어서,0.05 w/v% 내지 10 w/v%의 크산탄 검을 추가로 포함하는 것을 특징으로 하는 조영 매질.
- 제1항에 있어서,상기 삼투제를 0.005 w/v% 내지 60 w/v%의 양으로 포함하는 것을 특징으로 하는 조영 매질.
- 0.01 내지 0.2 w/v%의 황산바륨; 0.05 w/v% 내지 15 w/v%의 안정화제 및 1 w/v% 내지 25 w/v%의 소르비톨, 만니톨 및 크실리톨로 이루어진 군으로부터 선택되는 당계 삼투제를 포함하며, 0 내지 50의 하운스필드 값(Hounsfield value)을 가지는 것을 특징으로 하는, 개체의 해부학적 부분을 영상화하는 데 사용되는 조영 매질.
- 제11항에 있어서,상기 안정화제가 크산탄 검을 포함하고, 상기 삼투제는 소르비톨인 것을 특징으로 하는 조영 매질.
- 제11항에 있어서,0.05 내지 1 w/v%의 크산탄 검 및 1 내지 5 w/v%의 소르비톨을 포함하는 것을 특징으로 하는 조영 매질.
- 제11항에 있어서,상기 삼투제가 소르비톨인 것을 특징으로 하는 조영 매질.
- 제11항에 있어서,0.01 w/v% 내지 5 w/v%의 크산탄 검 및 1 w/v% 내지 15 w/v%의 소르비톨을 포함하는 것을 특징으로 하는 조영 매질.
- 제1항 또는 제11항에 있어서,상기 해부학적 부분이 위장관의 일부 또는 전부를 포함하는 것을 특징으로 하는 조영 매질.
- 제16항에 있어서,상기 위장관이 소장(small intestine), 결장(colon), 췌장(pancreas), 십이지장(duodenum), 맹장(cecum), 장(bowel), 대장(large intestine), 공장(jejunum), 회장(ileum), 충수(appendix), S자 결장(sigmoid), 직장(rectum), 및 위(stomach)를 포함하는 것을 특징으로 하는 조영 매질.
- 제1항 또는 제11항에 있어서,상기 조영 매질이 질병의 존재를 진단하는 데 이용되는 것을 특징으로 하는 조영 매질.
- 제18항에 있어서,상기 질병이, 췌장, 지라, 간, 담낭, 림프절, 또는 맥관계(vascular system)의 궤양(ulceration), 장애(lesion) 및 종양(tumor)으로 이루어진 군으로부터 선택되는 것을 특징으로 하는 조영 매질.
- 제18항에 있어서,상기 질병이 감염성 장 질환, 크론병(Crohn's Disease), 궤양성 또는 과민성 장 증후군인 것을 특징으로 하는 조영 매질.
- 제1항 또는 제11항에 있어서,상기 삼투제를 2 w/v% 내지 2.9 w/v%의 양으로 포함하는 것을 특징으로 하는 조영 매질.
- 제7항 또는 제11항에 있어서,상기 안정화제를 0.09 w/v% 내지 0.52 w/v%의 양으로 포함하는 것을 특징으로 하는 조영 매질.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/679,052 | 2003-10-03 | ||
US10/679,052 US7498018B2 (en) | 2003-10-03 | 2003-10-03 | Contrast media for use in medical and diagnostic procedures and methods of using the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057020825A Division KR20060052675A (ko) | 2003-10-03 | 2004-09-30 | 의료 및 진단 절차에 사용하기 위한 조영제 및 그 이용방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080112426A KR20080112426A (ko) | 2008-12-24 |
KR100992981B1 true KR100992981B1 (ko) | 2010-11-08 |
Family
ID=34394083
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057020825A KR20060052675A (ko) | 2003-10-03 | 2004-09-30 | 의료 및 진단 절차에 사용하기 위한 조영제 및 그 이용방법 |
KR1020087029742A KR100992981B1 (ko) | 2003-10-03 | 2004-09-30 | 의료 및 진단 절차에 사용하기 위한 조영제 및 그 이용 방법 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057020825A KR20060052675A (ko) | 2003-10-03 | 2004-09-30 | 의료 및 진단 절차에 사용하기 위한 조영제 및 그 이용방법 |
Country Status (8)
Country | Link |
---|---|
US (2) | US7498018B2 (ko) |
EP (1) | EP1677677B1 (ko) |
JP (1) | JP4874802B2 (ko) |
KR (2) | KR20060052675A (ko) |
CN (1) | CN1863483A (ko) |
AU (1) | AU2004277999B2 (ko) |
CA (2) | CA2747947A1 (ko) |
WO (1) | WO2005032369A1 (ko) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100382756C (zh) * | 2006-06-07 | 2008-04-23 | 华中科技大学 | 在数字减影血管造影图像中分割血管数据的方法 |
US9585973B1 (en) * | 2008-06-05 | 2017-03-07 | Peter Quagliano | Palatable liquid dilution vehicles for oral contrast agents |
US9585836B2 (en) * | 2008-06-05 | 2017-03-07 | Peter Quagliano | Palatable liquid dilution vehicles for oral contrast agents |
AU2010232430B2 (en) * | 2009-04-03 | 2014-08-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Magnetic microstructures for magnetic resonance imaging |
US9014787B2 (en) * | 2009-06-01 | 2015-04-21 | Focal Therapeutics, Inc. | Bioabsorbable target for diagnostic or therapeutic procedure |
WO2012082874A2 (en) | 2010-12-14 | 2012-06-21 | The Johns Hopkins University | Use of non-labeled sugars and detection by mri for assessing tissue perfusion and metabolism |
US8798716B1 (en) * | 2011-11-03 | 2014-08-05 | Solstice Corporation | Fiducial markers and related methods |
US20130289389A1 (en) | 2012-04-26 | 2013-10-31 | Focal Therapeutics | Surgical implant for marking soft tissue |
EP3171820B1 (en) | 2014-07-25 | 2022-11-16 | Hologic, Inc. | Implantable devices and techniques for oncoplastic surgery |
CN107670041B (zh) * | 2015-02-12 | 2020-07-31 | 中国医科大学附属第一医院 | 一种配置二氧化锆复合纳米材料分散液的方法 |
CN105079828B (zh) * | 2015-08-31 | 2018-03-23 | 山东师范大学 | 一种通用型口服腹部胃肠道影像检查助显剂及其制备方法 |
EP3392804A1 (en) * | 2017-04-18 | 2018-10-24 | Koninklijke Philips N.V. | Device and method for modelling a composition of an object of interest |
US11219502B2 (en) | 2017-09-11 | 2022-01-11 | Medtronic Advanced Energy, Llc | Transformative shape-memory polymer tissue cavity marker devices, systems and deployment methods |
US11324567B2 (en) | 2018-02-01 | 2022-05-10 | Medtronic Advanced Energy, Llc | Expandable tissue cavity marker devices, systems and deployment methods |
US11879953B2 (en) * | 2019-05-09 | 2024-01-23 | The General Hospital Corporation | System and method to evaluate upper gastrointestinal tract motility and emptying using magnetic resonance imaging (MRI) |
CN110201190B (zh) * | 2019-06-27 | 2021-12-14 | 施瑞华 | 一种用于食管癌早期诊断的染色剂及其制备方法 |
CN111631686B (zh) * | 2020-05-18 | 2022-03-15 | 湖南大学 | 一种利用核磁共振成像监测胃酸pH值的胶囊及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100354644B1 (ko) * | 1993-04-23 | 2002-12-28 | 노파르티스 아게 | 방출조절성약물전달장치 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD23830A (ko) * | ||||
DE23830C (de) * | H. SlERCKE in Harburg und G. DITTMAR in Berlin SW-, Gneisenaustr. 1 | Kochapparat mit Petroleumheizung | ||
IT1164372B (it) * | 1983-08-04 | 1987-04-08 | Bracco Ind Chimica Spa | Procedimento per la preparazione di solfato di bario con fluidita' e densita' accresciute, adatto quale componente opacizzante nei mezzi di contrasto, prodotto ottenuto con questo procedimento e relativi mezzi di contrasto allestiti |
US5077036A (en) * | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
JP2722218B2 (ja) * | 1988-09-22 | 1998-03-04 | 太田製薬株式会社 | 大腸x線検査用硫酸バリウム造影剤 |
GB9020091D0 (en) * | 1990-09-14 | 1990-10-24 | Nycomed As | Contrast media |
US5242455A (en) * | 1991-05-03 | 1993-09-07 | University Of Pittsburgh | Imaging fixation and localization system |
SE9101709L (sv) * | 1991-06-03 | 1992-12-04 | Karlshamns Lipidteknik Ab | Lipidderivat som diagnostikum eller kontrastmedel |
JP2833309B2 (ja) * | 1991-10-30 | 1998-12-09 | 堺化学工業株式会社 | Ct用硫酸バリウム造影剤 |
US5260049A (en) * | 1992-05-01 | 1993-11-09 | Sterling Winthrop Inc. | X-ray contrast compositions comprising alkoxyphenols |
JP3332426B2 (ja) * | 1992-10-02 | 2002-10-07 | 太田製薬株式会社 | 大腸および小腸の検査用x線造影剤 |
US5310538A (en) * | 1993-03-11 | 1994-05-10 | Sterling Winthrop Inc. | Compositions of iodophenoxy alkylene ethers in film-forming materials for visualization of the gastrointestinal tract |
US5424142A (en) * | 1993-05-20 | 1995-06-13 | E-Z-Em, Inc. | Negative contrast agents for magnetic resonance imaging comprising barium sulfate and a clay |
US5611342A (en) * | 1994-02-15 | 1997-03-18 | Molecular Biosystems, Inc. | Method of computer tomography imaging the gastrointestinal tract and surrounding upper abdominal tissues and organs using an orally administered low density contrast medium |
US5736121A (en) * | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
US5920319A (en) * | 1994-10-27 | 1999-07-06 | Wake Forest University | Automatic analysis in virtual endoscopy |
US5782762A (en) * | 1994-10-27 | 1998-07-21 | Wake Forest University | Method and system for producing interactive, three-dimensional renderings of selected body organs having hollow lumens to enable simulated movement through the lumen |
DE19535428C2 (de) * | 1995-05-26 | 1997-08-28 | Goldham Arzneimittel Gmbh | Bariumsulfat-haltiges Kontrastmittel für diagnostische Zwecke |
US5702682A (en) * | 1995-12-01 | 1997-12-30 | Hercules Incorporated | Methods for preparing radiopaque medical devices |
JP3717007B2 (ja) * | 1995-12-08 | 2005-11-16 | 和三 平井 | 新規なバリウム粉末製剤、それを用いた上部消化管造影用極超高濃度バリウム懸濁液、およびこれらの製造方法 |
US6125295A (en) * | 1997-08-27 | 2000-09-26 | Cash, Jr.; Webster C. | Pharmaceutically enhanced low-energy radiosurgery |
JP2001048810A (ja) * | 1999-08-04 | 2001-02-20 | Ina Food Ind Co Ltd | 造影剤用増粘剤 |
AUPQ605500A0 (en) * | 2000-03-07 | 2000-03-30 | Medefield Pty Ltd | Stool marker |
US6477401B1 (en) * | 2000-03-10 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Colonography of an unprepared colon |
US6517465B2 (en) * | 2000-04-20 | 2003-02-11 | Case, Llc | Method for controlling the drive mechanism of a vehicle |
JP5160723B2 (ja) * | 2002-04-06 | 2013-03-13 | ブラッコ ディアグノスティックス,インク. | 結腸残留物標識付加システム |
-
2003
- 2003-10-03 US US10/679,052 patent/US7498018B2/en active Active
-
2004
- 2004-09-30 KR KR1020057020825A patent/KR20060052675A/ko active Application Filing
- 2004-09-30 AU AU2004277999A patent/AU2004277999B2/en not_active Ceased
- 2004-09-30 CN CNA200480028911XA patent/CN1863483A/zh active Pending
- 2004-09-30 JP JP2006534192A patent/JP4874802B2/ja not_active Expired - Fee Related
- 2004-09-30 EP EP04789495.1A patent/EP1677677B1/en active Active
- 2004-09-30 CA CA2747947A patent/CA2747947A1/en not_active Abandoned
- 2004-09-30 KR KR1020087029742A patent/KR100992981B1/ko active IP Right Grant
- 2004-09-30 CA CA2540442A patent/CA2540442C/en active Active
- 2004-09-30 WO PCT/US2004/032502 patent/WO2005032369A1/en active Application Filing
-
2009
- 2009-01-16 US US12/355,149 patent/US20090136426A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100354644B1 (ko) * | 1993-04-23 | 2002-12-28 | 노파르티스 아게 | 방출조절성약물전달장치 |
Also Published As
Publication number | Publication date |
---|---|
US20050074405A1 (en) | 2005-04-07 |
KR20060052675A (ko) | 2006-05-19 |
US20090136426A1 (en) | 2009-05-28 |
WO2005032369A1 (en) | 2005-04-14 |
JP4874802B2 (ja) | 2012-02-15 |
AU2004277999A1 (en) | 2005-04-14 |
US7498018B2 (en) | 2009-03-03 |
CA2540442C (en) | 2011-09-27 |
EP1677677B1 (en) | 2019-09-11 |
CA2747947A1 (en) | 2005-04-14 |
AU2004277999B2 (en) | 2008-08-28 |
EP1677677A1 (en) | 2006-07-12 |
CN1863483A (zh) | 2006-11-15 |
EP1677677A4 (en) | 2011-01-12 |
JP2007507535A (ja) | 2007-03-29 |
CA2540442A1 (en) | 2005-04-14 |
KR20080112426A (ko) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090136426A1 (en) | Contrast media for using in medical and diagnostic procedures and methods of using the same | |
CN107847445B (zh) | 包封的气体或部分真空ct造影材料 | |
US8343462B2 (en) | Formulations for use in medical and diagnostic procedures | |
JP3332426B2 (ja) | 大腸および小腸の検査用x線造影剤 | |
CN117018234A (zh) | 硅酮基肠道ct对比材料 | |
JPS61500849A (ja) | 造影剤およびその使用方法 | |
JP2722218B2 (ja) | 大腸x線検査用硫酸バリウム造影剤 | |
Gembala et al. | Carcinoid of the intrahepatic ducts | |
Banerjee et al. | Epitheloid haemangioendothelioma of liver: a vascular tumour easily mistaken for metastatic carcinoma on ultrasound imaging | |
Sireci | Clinical utility of barium sulfate products: Formulation determines appropriate use | |
RU2234250C1 (ru) | Способ исследования состояния поджелудочной железы и селезенки | |
Gedroyc et al. | Practical CT techniques | |
US7384624B2 (en) | Oral contrast and method of producing the oral contrast | |
Valverde et al. | Radiographic imaging of nonhuman primates | |
Hudson et al. | Diagnostic Imaging of the Feline Patient | |
Oldendorf et al. | Digital spiral CT angiography of the aorta and its main branches | |
Girling | Ferrets: diagnostic imaging | |
Dawson | CONTRAST ENHANCEMENT IN CT | |
Van der Plaats et al. | Radiographic Examinations Using Contrast Media | |
Skalpe et al. | Clinical Use of Iodinated Contrast Media for the Visualization of Vessels, Organs and Organ Systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131023 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141023 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151023 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161021 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171020 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181023 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20191025 Year of fee payment: 10 |